ProPhase Labs Files 8-K

Ticker: PRPH · Form: 8-K · Filed: Dec 19, 2025 · CIK: 868278

Prophase Labs, INC. 8-K Filing Summary
FieldDetail
CompanyProphase Labs, INC. (PRPH)
Form Type8-K
Filed DateDec 19, 2025
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.0005
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, corporate-events

TL;DR

ProPhase Labs filed an 8-K on 12/19 for a 12/12 event. Details TBD.

AI Summary

ProPhase Labs, Inc. filed an 8-K on December 19, 2025, reporting an event that occurred on December 12, 2025. The filing pertains to "Other Events" and "Financial Statements and Exhibits" but does not specify the exact nature of these events or any associated financial figures within the provided text.

Why It Matters

This 8-K filing indicates a material event has occurred for ProPhase Labs, Inc., requiring disclosure to investors. However, the specific details of the event are not immediately clear from the provided filing header.

Risk Assessment

Risk Level: low — The filing is a standard 8-K disclosure and does not inherently contain negative information or significant financial risk based on the provided text.

Key Players & Entities

FAQ

What specific event triggered this 8-K filing for ProPhase Labs, Inc. on December 12, 2025?

The provided text for the 8-K filing does not specify the exact nature of the 'Other Events' or 'Financial Statements and Exhibits' that were reported.

What is the primary business of ProPhase Labs, Inc.?

ProPhase Labs, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, with SIC code 2834.

When was ProPhase Labs, Inc. incorporated and in which state?

ProPhase Labs, Inc. was incorporated in Delaware.

What is the principal executive office address for ProPhase Labs, Inc.?

The principal executive offices are located at 626 RXR Plaza, 6th Floor, Uniondale, New York 11556.

Has ProPhase Labs, Inc. undergone a name change previously?

Yes, the company was formerly known as QUIGLEY CORP, with a date of name change on March 28, 1993.

Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2025-12-19 13:07:33

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ProPhase Labs, Inc. By: /s/ Ted Karkus Ted Karkus Chairman of the Board and Chief Executive Officer Date: Friday, December 19, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing